case_images: PMC4348588_01
case_images: Posteroanterior and lateral chest X-rays of the patient.
case_images: CRIPU2015-356796.001.jpg
case_images: PMC4348588_01_CRIPU2015-356796.001.jpg
case_images: fig1
case_images: Routine blood tests and chest X-ray were normal (Figure 1).
case_images: Chest CT showed a lesion protruding to the lumen in distal trachea at the posterior wall.
case_images: CRIPU2015-356796.002.jpg
case_images: PMC4348588_01_CRIPU2015-356796.002.jpg
case_images: fig2
case_images: At chest computed tomography (CT) a mass was seen at the distal trachea, nearly obstructing the lumen (Figure 2).
case_images: Bronchoscopic view of the lesion, causing 80% obstruction at the tracheal lumen.
case_images: CRIPU2015-356796.003.jpg
case_images: PMC4348588_01_CRIPU2015-356796.003.jpg
case_images: fig3
case_images: At fiberoptic bronchoscopic (FOB) evaluation, there was a papillomatous lesion at the posterolateral wall of the distal 1/3 of trachea, causing ~80% obstruction at the lumen (Figure 3).
case_images: Bronchoscopic view, tracheal wall after excision of the lesion with cryotherapy.
case_images: CRIPU2015-356796.004.jpg
case_images: PMC4348588_01_CRIPU2015-356796.004.jpg
case_images: fig4
case_images: In the pathology, squamous epithelial hyperplasia of bronchial epithelium with small papillomatous structures was seen (Figure 4).
case_images: Papillary structures made by hyperplastic squamous epithelium are seen in fibrovascular core (H&E, x40), and koilocytic cells with perinuclear vacuolisation are seen in hyperplastic squamous epithelium (H&E, x200).
case_images: CRIPU2015-356796.005.jpg
case_images: PMC4348588_01_CRIPU2015-356796.005.jpg
case_images: fig5
case_images: There were no dysplastic changes in the epithelial cells (Figure 5).
case_images: CT sections at the 6th month: tracheal lumen is normal.
case_images: CRIPU2015-356796.006.jpg
case_images: PMC4348588_01_CRIPU2015-356796.006.jpg
case_images: fig6
case_images: Computed tomography and bronchoscopic evaluation at the 3rd month of the treatment showed no recurrence (Figure 6) and IFN-alpha treatment was continued for 6 months.